Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Study reveals mangos attenuates potential against colon cancer

The chemo-preventive potential of Mangiferin (MF) (mango).

10 Jan 2024

Carvedilol improves heart health marker in childhood cancer survivors

Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children's Oncology Group (COG), have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.

9 Jan 2024

Hidden identity of blood cancer revealed

Leukemia is a common term used to refer to a form of blood cancer. However, there are different types of leukemia depending on the cell type involved.

9 Jan 2024

AI reveals hidden rules of cell neighborhoods in cancer

Researchers from Children's Hospital of Philadelphia have developed a new AI-powered algorithm to help understand how different cells organize themselves into particular tissues and communicate with one another.

8 Jan 2024

Fruit fly research solves human disease and fuels new cancer immunotherapy approach

Scientists have solved a cellular murder mystery nearly 25 years after the case went cold. Following a trail of evidence from fruit flies to mice to humans revealed that cannibalistic cells likely cause a rare human immunodeficiency.

5 Jan 2024

Metabolically armored CAR-T cells demonstrate lasting efficacy against solid tumors

At EPFL's School of Engineering, Professor Li Tang's Laboratory of Biomaterials for Immunoengineering has made significant strides in cancer treatment research.

4 Jan 2024

Radon exposure linked to increased risk of blood cell mutation in female stroke patients

Radon, a naturally occurring radioactive gas produced when metals like uranium or radium break down in rocks and soil, is a known cause of lung cancer.

3 Jan 2024

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

28 Dec 2023

Embryonic immune sensor could key to creating patient-derived blood stem cells

A microbial sensor that helps identify and fight bacterial infections also plays a key role in the development of blood stem cells, valuable new insight in the effort to create patient-derived blood stem cells that could eliminate the need for bone marrow transplants.

19 Dec 2023

Trends in mortality from leading cancers from 2002 to 2019 for the 314 districts in England

Researchers assessed mortality trends in the leading cancers from 2002 to 2019 across 314 districts in England using high-resolution spatiotemporal analysis.

14 Dec 2023

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

11 Dec 2023

Survival rates of black patients with leukemia soar with modern therapies

Non-Hispanic Black patients with acute myeloid leukemia (AML) are living longer, now that new therapies are available, according to a study presented by researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

11 Dec 2023

Personalized treatment for leukemia results in longer life and fewer side effects

Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase III trial has found.

11 Dec 2023

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of the treatment plan.

11 Dec 2023

New combinations and targeted therapies for acute myeloid leukemia on the horizon

The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.

11 Dec 2023

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Leukemia News and Research

Further Reading

Study reveals mangos attenuates potential against colon cancer

Carvedilol improves heart health marker in childhood cancer survivors

Hidden identity of blood cancer revealed

AI reveals hidden rules of cell neighborhoods in cancer

Fruit fly research solves human disease and fuels new cancer immunotherapy approach

Metabolically armored CAR-T cells demonstrate lasting efficacy against solid tumors

Radon exposure linked to increased risk of blood cell mutation in female stroke patients

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

Embryonic immune sensor could key to creating patient-derived blood stem cells

Trends in mortality from leading cancers from 2002 to 2019 for the 314 districts in England

New combination treatment offers hope for older patients with mantle cell lymphoma

Survival rates of black patients with leukemia soar with modern therapies

Personalized treatment for leukemia results in longer life and fewer side effects

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

New combinations and targeted therapies for acute myeloid leukemia on the horizon

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News